TWP
ABBV icon

Tempus Wealth Planning’s AbbVie ABBV Stock Holding History

Tempus Wealth Planning’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
4,457
+42
+1% +$9.04K 0.22% 117
2026
Q1 		$960K Buy
4,415
+15
+0.3% +$3.33K 0.22% 123
2025
Q4 		$1.01M Sell
4,400
-761
-15% -$173K 0.23% 115
2025
Q3 		$1.19M Buy
5,161
+624
+14% +$127K 0.27% 98
2025
Q2 		$842K Buy
4,537
+1,650
+57% +$307K 0.21% 122
2025
Q1 		$605K Sell
2,887
-199
-6% -$38.7K 0.18% 128
2024
Q4 		$548K Buy
3,086
+68
+2% +$12.5K 0.17% 133
2024
Q3 		$596K Buy
3,018
+151
+5% +$28.2K 0.22% 111
2024
Q2 		$492K Buy
2,867
+299
+12% +$49.5K 0.21% 112
2024
Q1 		$468K Buy
2,568
+251
+11% +$43.3K 0.21% 116
2023
Q4 		$359K Hold
2,317
– – 0.16% 134
2023
Q3 		$345K Sell
2,317
-2,333
-50% -$342K 0.17% 113
2023
Q2 		$626K Sell
4,650
-175
-4% -$25.7K 0.28% 92
2023
Q1 		$769K Buy
4,825
+226
+5% +$34.6K 0.38% 69
2022
Q4 		$743K Buy
4,599
+349
+8% +$53.5K 0.45% 69
2022
Q3 		$570K Buy
4,250
+363
+9% +$52.1K 0.38% 73
2022
Q2 		$595K Buy
3,887
+12
+0.3% +$1.83K 0.49% 59
2022
Q1 		$628K Sell
3,875
-398
-9% -$57.8K 0.45% 60
2021
Q4 		$579K Sell
4,273
-9
-0.2% -$1.06K 0.31% 85
2021
Q3 		$462K Buy
4,282
+357
+9% +$40.8K 0.26% 98
2021
Q2 		$442K Buy
3,925
+149
+4% +$16.8K 0.29% 94
2021
Q1 		$409K Buy
3,776
+15
+0.4% +$1.6K 0.43% 59
2020
Q4 		$403K Sell
3,761
-159
-4% -$15.3K 0.52% 41
2020
Q3 		$343K Buy
3,920
+15
+0.4% +$1.41K 0.5% 47
2020
Q2 		$383K Buy
3,905
+188
+5% +$16.6K 0.57% 34
2020
Q1 		$283K Sell
3,717
-71
-2% -$6.05K 0.46% 48
2019
Q4 		$335K Buy
+3,788
New +$314K 0.3% 57

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tempus Wealth Planning's ABBV Position: Q2 2026 in Review

Tempus Wealth Planning increased its AbbVie (ABBV) stake by 0.95% in Q2 2026, buying an estimated $9.04K and bringing the position to 4,457 shares worth $1.12M. The position accounts for 0.22% of the portfolio, ranked #117.

Tempus Wealth Planning first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.19M in Q3 2025. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Tempus Wealth Planning held 4,457 shares of AbbVie worth $1.12M as of Q2 2026.
  • Tempus Wealth Planning bought 42 AbbVie shares in Q2 2026, an estimated $9.04K.
  • AbbVie made up 0.22% of Tempus Wealth Planning's portfolio in Q2 2026, its #117 holding.
  • Tempus Wealth Planning first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Tempus Wealth Planning's AbbVie position peaked at $1.19M in Q3 2025.
  • 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Tempus Wealth Planning's 13F filing for Q2 2026, filed 22 Jul 2026.